Navigation Links
CEL-SCI Presents Long-Term Cancer Survival Data With Multikine

Multikine Improves Overall Survival by 33% 3.5 Years Post Surgery

VIENNA, Va., May 21, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announced today that its cancer drug Multikine(R) was shown to significantly increase long term overall survival in a Phase II study of head and neck cancer patients. The data were presented on May 20, 2007 at the First International Congress of the International Association of Oral Oncology in Amsterdam, the Netherlands, by Dr. Eyal Talor, Senior VP of Research and Manufacturing at CEL-SCI Corporation.

Dr. Talor's presentation focused on the results obtained in CEL-SCI's final Phase II clinical trial of Multikine that was conducted in patients with head and neck cancer (oral squamous cell carcinoma -- OSCC). This final Phase II clinical trial was designed to assess thoroughly the positive safety and efficacy observations made in patients treated with Multikine in CEL-SCI's early Phase II trials. In the trial Multikine was given prior to standard care to recently diagnosed and not yet treated cancer patients.

The addition of Multikine to the first treatment (standard of care) of these patients resulted in a 33% improvement in the median overall survival at 3-1/2 years post-surgery, when compared to the survival results reported in 55 OSCC clinical trials published in the scientific literature between 1987 and 2007.

Multikine first-line treatment also resulted in an improvement of the 2- year local regional over the published local regional control rate. It is clinically recognized that recurrence of disease in head and neck cancer is associated with a very poor prognosis. Multikine treatment did not result in any severe adverse events (SAE) in this Phase II clinical trial and no SAEs related to Multikine have been reported in other trials conducted with Multikine either.

CEL-SCI received clearance from the United States Food and Drug Administration
'"/>




Page: 1 2 3

Related medicine technology :

1. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
2. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: CEL SCI Presents Long Term Cancer Survival Data With Multikine
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/ctd7zx/europe ) has announced the addition of ... (2014 - 2019)" report to their offering. ... Germany . This is followed by UK and ... Poland are the fastest growing segments. ... the basis of Product (Film Screen, Digital, 3D, Analog Systems, ...
(Date:6/2/2015)... Texas , June 2, 2015 ... report defines and segments the concerned market with ... valued at $261.8 million in 2014, and is ... a CAGR of 19.3% from 2014 to 2019. ... America Mannequin-Based Simulation Market for an analysis of ...
(Date:6/2/2015)... 2015 Intarcia Therapeutics, Inc. today ... its recently announced synthetic royalty / equity convert financing, ... have purchased Convertible Limited Recourse Notes from Intarcia and ... of any future global net sales of ITCA 650 ... also have the option, commencing upon U.S. regulatory approval ...
Breaking Medicine Technology:Europe Mammography Market Report 2014-2019 - Growth, Trends And Forecasts 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 2North America Mannequin-Based Simulation Market is Expected to Reach $632.5 Million by 2019, at a CAGR of 19.3% From 2014 to 2019 3Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 2Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million 3
...  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... results on Thursday, April 26, 2012, before the U.S. financial ... 8:30 AM EDT that day. Live audio ... link to the webcast may be accessed from the ,Events ...
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) ... subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to ... DS Healthcare Limited to assist in introducing Clotamin to ... the agreement, DS Healthcare will evaluate the Clotamin formulation ...
Cached Medicine Technology:Sunpeaks Ventures Enters Agreement with UK Based Healthcare Firm to Introduce Clotamin to UK and European Union Countries 2
(Date:6/2/2015)... 02, 2015 Erbelli’s Gourmet Pizzeria, Italian ... promote its handmade gourmet pizzas and calzones, fresh wraps, ... website is new, the recipes are not—they have been ... main feature of the site is the menu, which ... descriptions of all the items. You can order directly ...
(Date:6/2/2015)... Claflin Medical Equipment , a ... acquisition of RSI Equipment, Inc ., a ... 2015. , With CME’s recent merger of Hospital ... three premier organizations which specialize in the procurement and ... By combining forces, they now cover the entire country ...
(Date:6/2/2015)... ZOOM+, the Portland-based health innovator of on-demand ... today the opening of its on-demand ZOOM+Smile studio. ZOOM+Smile ... complete dental exam, cleaning and whitening in 57 minutes, ... ZOOM+ services, ZOOM+Smile can be scheduled by mobile phone ... be as inviting as your favorite coffee shop?” said ...
(Date:6/2/2015)... Acara Partners has seen a spike in demand for ... as is now required by recent Google search algorithm changes. ... several new clients in the medical aesthetics vertical, are anxious ... meet Google’s new requirements,” commented Fran Acunzo, CEO of Acara ... education, non-profits, and the business world.” , Back in ...
(Date:6/2/2015)... Vancouver, BC (PRWEB) June 02, 2015 ... to announce the opening of Surrey’s first ... cities and boasts a diverse, young community, ... communities. http://www.theglobeandmail.com/news/british-columbia/four-reasons-bcs-fastest-growing-city-is-a-political-powerhouse/article21408253/ , Until now ... have had to come into Vancouver ...
Breaking Medicine News(10 mins):Health News:Erbelli’s of Bradenton Launches New Mobile-Friendly Website 2Health News:Claflin Medical Equipment (CME) Announces Acquisition of RSI Equipment, Inc. 2Health News:ZOOM+ Opens Its First On-Demand ZOOM+Smile Studio and Reinvents the Dental Exam 2Health News:Acara Partners Expands Website and Digital Offerings 2Health News:Olive Fertility Centre Opens First Fertility Clinic in Surrey BC 2
... Vendome Group, publishers of HEALTHCARE DESIGN and ... The Center for Health Design (CHD), a nonprofit research, ... development of a 2-day educational track for HEALTHCARE DESIGN.09 ... engineering technologies of healthcare facilities. , , The ...
... one-third of Americans use complementary or alternative medicine (CAM). ... to, rather than instead of, a conventional medical regimen. ... place at the point of care, "The ACP Evidence-Based ... resource for clinicians and patients. "The book is ...
... ... is now a featured expert on searchvitaminsupplements.com, a new informational Web site devoted to ... , ... (PRWEB) July 8, 2009 -- Dr. Stephen Sinatra , a board-certified cardiologist, nutritionist, ...
... Gold,s Gym, the world,s leading authority on health and ... epidemic by once again supporting the American Diabetes Association,s Tour ... company is the Tour de Cure,s top national fundraiser and, ... raised more than $350,000. , , Since Gold,s ...
... N.Y., July 8 VirtualScopics, Inc. (Nasdaq: VSCP ... announced revenues for the second quarter ended June 30, 2009 ... the comparable period in 2008. , , "We ... growth," stated Jeff Markin, President and Chief Executive Officer of ...
... been presented with the prestigious Amethyst Award from the Ontario ... 2009 from the Premier of Ontario, Dalton McGuinty, in recognition ... combating air pollution in Canada and the United States. ... Air Quality, Atmosphere & Health and has co-authored ...
Cached Medicine News:Health News:HEALTHCARE DESIGN.09 Adds a New Construction and Engineering Track 2Health News:HEALTHCARE DESIGN.09 Adds a New Construction and Engineering Track 3Health News:Evidence-based information about complementary and alternative medicine treatments now available 2Health News:Board-Certified Cardiologist Dr. Stephen Sinatra Featured on Searchvitaminsupplements.com 2Health News:Team Gold's Gym Continues to Lead the National Fight Against Diabetes 2Health News:Team Gold's Gym Continues to Lead the National Fight Against Diabetes 3Health News:VirtualScopics Reports Record Revenue 2
... Vessel Dissector has application for use in ... the extraperitoneal spaces such as the retroperitoneal, ... be used in surgical procedures requiring dissection ... harvesting of a quality conduit through a ...
... The Thoratec VAD System includes three ... Drive Console or TLC-II Portable Driver. This ... when the natural heart, with conventional therapy, ... perfuse vital organs. To accomplish support, blood ...
... two distinct polyethylene glycol polymers that combine to ... to chemically bond to each other, as well ... material forms a flexible, watertight seal that remains ... withstand arterial pressure. It is completely resorbed by ...
The Icy catheter is inserted into the femoral vein and resides in the inferior vena cava. Saline flow within the balloons creates a proprietary vortex flow pattern which maximizes heat exchange with...
Medicine Products: